

Ceva Santé Animale has been the fastest growing Top 10 veterinary health company since our creation in 1999. Our expertise centres on the two fields of pharmacology and biology, where we have dedicated teams that aim to meet the specific demands of the companion animal, poultry, ruminant and swine sectors. We continually strive to find better solutions to existing and emerging diseases which will in turn improve animal health and productivity.

Our care extends beyond animal health and welfare. These days, a staggering 75% of all emerging human infectious diseases are of animal origin. Ceva is involved in the fight against the spread of infectious disease that can be transmitted from wild or domestic animals and birds to humans – diseases known as zoonoses, which include avian flu, brucellosis and Q-fever.

Ceva is a visible supporter of and contributor to various welfare and social programmes all over the world. Our work ranges from researching, developing, producing and supplying animal health products to the poorest livestock owners in the world, of which our programme with the Bill & Melinda Gates Foundation, to produce more faster growing

chickens in West Africa, is a good example; to supplying assistance dogs training with Adaptil® collars, to calm and reassure puppies improving overall pass rates.

Ceva successfully combines profitability with long-term growth.

Our global business operations are divided into five major zones: Western Europe, North America/Pacific, Latin America, Africa/Middle-East/Eastern Europe/Turkey and Asia.

We are directly present in 46 countries, have 12 research and development centres, 25 production sites and 5500 employees worldwide. The company is focused on the research, development, production and marketing of pharmaceutical products and vaccines for companion animal, poultry, ruminant and swine.

